AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02986711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Text Messages
Description: Motivational text messages in addition to survey questions about smoking status
Study NCT02986711 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Only survey questions about smoking status
Study NCT00858026 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Breastmilk
Description: Exclusively breastfed babies
Study NCT00858026 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard milk
Description: Weaning babies fed with the standard formula
Study NCT00858026 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fermented milk
Description: Weaning babies fed with the fermented formula
Study NCT01454791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: diclofenac sodium topical gel
Description: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
Study NCT01454791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: diclofenac sodium topical gel
Description: diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
Study NCT01454791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: a placebo gel is applied 1-4 times per day for two weeks.
Study NCT01454791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: a placebo gel is applied 1-4 times per day for two weeks.
Study NCT01467505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telaprevir
Description: Tablet
Study NCT01467505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Tablet
Study NCT01467505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon Alfa-2a
Description: Subcutaneous Injection
Study NCT01467505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunosuppressant Regimen
Description: Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
Study NCT02719171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: risankizumab
Description: Risankizumab administered by SC injection
Study NCT02719171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo for risankizumab
Description: Placebo for risankizumab administered by SC injection
Study NCT00227721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
Study NCT02463110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03732404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: preoperative carbohydrate loading
Description: Patients in the treatment group will receive a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrin; 240 mOsm/L) in a dose of 800 mL. Patients will be free to drink the beverage from the evening before the operation and up to 2 hours before the induction of anesthesia
Study NCT03732404 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The control group will receive plain water with the same volume and timing of treatment.
Study NCT00227721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine hydrochloride
Description: 800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
Study NCT02264158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan high
Study NCT02264158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan low
Study NCT03745261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (Ventolin®)
Description: According to the revised 2017 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol will be used to Group A patients: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
Study NCT02264158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacidipine high
Study NCT02264158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacidipine low
Study NCT02264158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidipine low
Study NCT02264158 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03826121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sesame Oil Cake Extract
Description: Sesame Oil Cake Extract 1.5 g/day for 12 weeks.
Study NCT03826121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo for 12 weeks.
Study NCT03476148 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home Rehabilitation using Interactive device
Description: Rehabilitation is performed using interactive motion tracking augmented reality device. 6 exercises are included in one-day rehabilitation program. Each exercise is recorded in aspect of compliance, completion.
Study NCT03476148 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Rehabilitation
Description: Patients are given the exercises in the setting of inpatient rehabilitation
Study NCT00905463 — intervention group
Intervention type: PROCEDURE
Intervention: Lung transplantation
Description: Lung transplantation
Study NCT01029184 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: commercialized complete cereals
Description: complete cereals suitable for the weaning period
Study NCT01029184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: commercialized complete cereals with additional ingredient
Description: complete cereals suitable for weaning period
Study NCT03049917 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Conditional cash transfer upon HIV testing
Study NCT02620969 — intervention group
Intervention type: OTHER
Intervention: Blood and dialysate sampling
Description: Blood and dialysate sampling
Study NCT01550536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance and aerobic exercise
Description: Following baseline measurements, sedentary women were enrolled in a 16-week exercise training program at the YMCA in La Jolla, CA. Exercise occurred 3 times per week, for 1.5 hours each time. Exercise consisted of stretching, 20 minutes of aerobic exercise on elliptical machines, and 3 sets of 10-12 repetitions to failure for each of ten weight lifting exercises: abdominal crunch, arm curl, arm extension, chest press, lat pull-down, leg curl, leg extension, leg press, seated row, and trunk extension. Women started at 65-75% of 1-repetition-maximum, and resistance was increased as necessary to maintain the number of sets and reps and to continue to work to failure. Exercise was monitored by a TechnoGym electronic key system, and trainers instructed and supervised subjects in the gym.
Study NCT01425502 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: DQIP Intervention
Description: The DQIP intervention comprises of:~* Educational outreach~* Information technology application~* Financial incentives
Study NCT02534545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doctormate® (200mmHg)
Description: Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
Study NCT02534545 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Doctormate® (60mmHg)
Description: Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
Study NCT03947177 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: GMIT
Description: Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices.
Study NCT03947177 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMIT+
Description: Six 30-minute sessions delivered virtually in a group format. Each week a group facilitator will elicit adolescents' feedback on important topics related to substance use and provide experiential activities to help adolescents explore their beliefs and practice making healthy choices. Parents and/or guardians will virtually participate in parent-only support group sessions.
Study NCT03923257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-DOTA-tyr3-OCTREOTATE
Description: This is a peptide receptor radiotherapy that targets somatostatin receptors on tumor cells.
Study NCT03923257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peptide Receptor Radiotherapy (PRRT)
Description: PRRT is internal radiation that is individually dosed according to patient body surface area, kidney function and bone marrow status.
Study NCT01212861 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Suprachoroidal Dissection Instrument (SDI)
Description: The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
Study NCT03685955 — intervention group
Intervention type: BIOLOGICAL
Intervention: Amniotic membranes
Description: Amniotic membranes will be employed during participant's genitourinary reconstruction
Study NCT03745261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide (Spiriva®)
Description: Tiotropium Bromide Powder for Inhalation will be used to Group B and Group C patients: Tiotropium Bromide Powder for Inhalation(Spiriva®, Boehringer Ingelheim), 18μg/ capsule, 10 capsules. 18μg each time, once daily.
Study NCT03745261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol / fluticasone (Seretide®)
Description: Salmeterol / fluticasone will be used to Group D patients: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/250 μg / dose, 60 inhalations. 50/250 μg each time, twice daily.
Study NCT03745261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YCC capsule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Yong Chong Cao (YCC)capsule (Kecai®, Guangdong daguang pharmaceutical group Co., Ltd), 1 g each time, three times a day.
Study NCT01446627 — intervention group
Intervention type: OTHER
Intervention: There is no intervention for this study
Description: None, no intervention made.
Study NCT03745261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL capsule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bailing(BL) capsule (Bailing®, Huadong Medicine Co.,Ltd), 1 g each time, three times a day
Study NCT04360343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Film-coated tablet
Description: uncoated tablet
Study NCT01860287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.2 MG Sublingual Tablet
Description: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2)
Study NCT04360343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Film-coated tablet
Description: uncoated tablet
Study NCT01860287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive a placebo
Study NCT01860287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.4 MG Sublingual Tablet
Description: This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.4)
Study NCT02573194 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breakfasts varying in protein source content on appetite
Description: In this randomized, within-subject study, subjects are asked to consume 4 iso-energetic and iso-volumetric puddings as breakfast (20% of estimated energy requirements) with varying distribution of protein sources. The objective is to identify the protein source and the distribution on suppressing appetite.
Study NCT04088006 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Injection of STYLAGE® HydroMax
Description: STYLAGE® HydroMax is a hyaluronic acid injectable gel intended to improve skin moisturization and elasticity of the face and neckline area in this study.~A total of 3 injection sessions will be performed one month apart for each subject.~At each injection session, 1 mL of product will be injected in the mid to deep dermis of one cheek and another 1 mL in one site of neckline area for each subject.
Study NCT01871350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Daily intake for 10 weeks (+/- 2 weeks)
Study NCT01871350 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily intake for 10 weeks (+/- 2 weeks)
Study NCT02774967 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: root coverage
Description: Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,
Study NCT02774967 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: root coverage
Description: Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,
Study NCT01835418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: crossover comparison of amlodipine vs lisinopril
Study NCT01959477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV
Study NCT01959477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study NCT01959477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01959477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT01959477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo autologous peripheral blood stem cell transplant
Study NCT00994682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone study drug
Description: 30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of 18 months
Study NCT00994682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
Study NCT00994682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone Open Label
Description: Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
Study NCT00994682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pioglitazone Open Label
Description: Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
Study NCT02859324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-122
Study NCT02859324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Study NCT01052129 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen sodium
Description: Naproxen Sodium Tablets 550 mg
Study NCT01052129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen sodium
Description: Naproxen Sodium Tablets 550 mg
Study NCT03653325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORI measurement
Description: Oxygen (FiO2) will be titrated according to ORI index and Oxygen saturation.
Study NCT03653325 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: oxygen saturation measurement
Description: Oxygen (FiO2) will be titrated according to oxygen saturation
Study NCT03653325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxygen saturation measurement
Description: Oxygen (FiO2) will be titrated according to oxygen saturation
Study NCT01049217 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: Pregabalin 75 mg-300mg twice daily during the course of the study.
Study NCT01049217 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
Study NCT03546764 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous catheter
Description: tube inserted to drain hemothorax
Study NCT03546764 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous catheter
Description: tube inserted to drain hemothorax
Study NCT00531700 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health messaging
Description: Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects
Study NCT00531700 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health messages
Description: community level health messages unrelated to the study originating exposures
Study NCT02923492 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafERteens
Description: A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
Study NCT04011943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation
Study NCT04011943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Fecal Microbiota Transplantation
Description: Fecal Microbiota Transplantation
Study NCT01193426 — intervention group
Intervention type: OTHER
Intervention: Ascite liquid puncture
Description: Ascitic fluid obtained by paracentesis
Study NCT00903682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etravirine (ETR, TMC125)
Description: 400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
Study NCT00903682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: efavirenz (EFV)
Description: 600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
Study NCT03169101 — intervention group
Intervention type: DRUG
Intervention: Nicotine patch
Description: All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks.
Study NCT03169101 — intervention group
Intervention type: BEHAVIORAL
Intervention: Behavioral counseling
Description: Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
Study NCT03143946 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin supplement;
Description: Vitamin K, vitamin A, vitamin D, vitamin E, nicotinamide, vitamin B12
Study NCT03143946 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet advice
Study NCT04488718 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EnergieShake® Junior Powder Complete
Description: Oral Nutritional Supplement
Study NCT01204398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan+amlodipine fixed dose combination
Description: after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
Study NCT03443050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Unstable
Description: This group will train over unstable surfaces to enhance balance abilities
Study NCT03443050 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stable
Description: This group will train over stable surface to enhance balance abilities
Study NCT01375088 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: propolis
Description: 15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
Study NCT01375088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propolis
Description: 15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
Study NCT04351568 — intervention group
Intervention type: OTHER
Intervention: quesionnair
Description: questionnair about Emerging Legal and Ehical Disputes Over Patient Confidentiality